Medtronic advances abbott cgm partnership with fda submission of interoperable insulin pump

Galway, ireland , april 24, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the u.s. food and drug administration (fda) seeking clearance for an interoperable pump. fda clearance of this pump would pave the way for system integration with a continuous glucose monitoring (cgm) sensor based on abbott's most advanced cgm platform.
MDT Ratings Summary
MDT Quant Ranking